
The FDA approves durvalumab for bladder cancer and gefurulimab for myasthenia gravis, creating distinct ADC, biologic, and autoinjector production needs.
Nanoform’s Eric Peter talks about what Nanoform showcased at AAPS 2021and what makes Nanoform’s particle engineering solutions unique.






